Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.
AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX) shares increased 5.39 percent to close at $11.92 a share Tuesday. The stock traded between $11.35 and $12.01 on volume of 607,443 shares traded. Analysts at RBC Capital Markets have recently initiated coverage on the company with an "outperform" rating. Shares of AcelRx Pharmaceuticals have gained approximately 155.0 percent in the past year.
Find out more about AcelRx Pharmaceuticals including full access to the free equity report at:
www.RDInvesting.com/ACRX
Impax Laboratories Inc. (NASDAQ: IPXL) shares declined 2.82 percent to close at $24.51 a share Tuesday. The stock traded between $24.45 and $25.45 on volume of 556,490 shares traded. Analysts at RBC Capital Markets have recently initiated coverage on the company with a "sector perform" rating. Shares of Impax Laboratories have gained approximately 15.0 percent in the past year.
Find out more about Impax Laboratories including full access to the free equity report at:
www.RDInvesting.com/IPXL
Mylan Inc. (NASDAQ: MYL) shares increased 1.70 percent to close at $42.98 a share Tuesday. The stock traded between $42.30 and $43.47 on volume of 3.11 million shares traded. Analysts at RBC Capital Markets have recently initiated coverage on the company with an "outperform" rating. Shares of Mylan have gained approximately 52.0 percent in the past year.
Find out more about Mylan including full access to the free equity report at:
www.RDInvesting.com/MYL
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) shares increased 1.78 percent to close at $41.21 a share Tuesday. The stock traded between $40.36 and $41.33 on volume of 6.08 million shares traded. Analysts at RBC Capital Markets have recently initiated coverage on the company with a "sector perform" rating. Shares of Teva Pharmaceutical have gained approximately 8.0 percent in the past year.
Find out more about Teva Pharmaceutical including full access to the free equity report at:
www.RDInvesting.com/TEVA
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Research Driven Investing
[email protected]